Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.

  • Revenue in EUR (TTM)2.09bn
  • Net income in EUR276.75m
  • Incorporated1995
  • Employees4.82k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AFXX:GER since
announced
Transaction
value
DORC Dutch Ophthalmic Research Center (International) BVDeal completed15 Dec 202315 Dec 2023Deal completed2.62%1.08bn
Data delayed at least 15 minutes, as of Apr 24 2024 16:35 BST.

Institutional shareholders

12.71%Per cent of shares held by top holders
HolderShares% Held
DWS Investment GmbHas of 27 Mar 20241.86m2.08%
Comgest SAas of 29 Dec 20231.83m2.04%
Invesco Advisers, Inc.as of 29 Feb 20241.60m1.79%
Norges Bank Investment Managementas of 31 Dec 20231.40m1.57%
The Vanguard Group, Inc.as of 05 Apr 20241.30m1.45%
Candriam Belgium SAas of 31 Mar 2024889.09k0.99%
Allianz Global Investors GmbHas of 31 Jan 2024845.39k0.95%
BlackRock Fund Advisorsas of 04 Apr 2024647.20k0.72%
BlackRock Asset Management Deutschland AGas of 05 Apr 2024583.53k0.65%
BlackRock Advisors (UK) Ltd.as of 04 Apr 2024409.28k0.46%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.